Abstract
The phase II open-label GALAHAD study evaluated niraparib in mCRPC patients (pts) with DRD who had progressed on prior taxane-based chemotherapy and androgen signaling inhibitor therapy. We report on the HRQoL outcomes at final analysis.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
